<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01347580</url>
  </required_header>
  <id_info>
    <org_study_id>D5130L00006</org_study_id>
    <nct_id>NCT01347580</nct_id>
  </id_info>
  <brief_title>A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)</brief_title>
  <acronym>ATLANTIC</acronym>
  <official_title>A 30 Day International, Randomized, Parallel-group, Double-blind, Placebo-controlled Phase IV Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for PCI.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine whether initiation of ticagrelor as early as in the
      ambulance setting leads to a rapid reperfusion of the infarct-related artery therefore
      facilitating the Percutaneous Coronary Intervention (PCI) and optimizing the outcome for the
      patient.

      The study will assess the efficacy and safety of pre-hospital compared to in-hospital
      administration of ticagrelor in co-administration with aspirin, on restoring the blood flow
      in the occluded heart artery and improving the myocardial perfusion in patients suffering
      from myocardial infarction and planned to have a PCI. Patients can be randomised in either
      one of the 2 arms:

      re-hospital ticagrelor arm: Patients will receive a loading dose of 180 mg ticagrelor for the
      pre-hospital administration and placebo for in-hospital administration.

      or In-hospital ticagrelor arm: Patients will receive a placebo for pre-hospital
      administration and 180 mg ticagrelor loading dose for in-hospital administration.

      Patients are initially managed by ambulance physician/personnel in pre hospital settings.
      They are then transferred into a Catheterization room to undergo a PCI.

      After the administration of the loading dose of ticagrelor (double blind), patients will
      continue on ticagrelor 90 mg bid and be followed in study for 30 days post randomisation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Thrombolysis In Myocardial Infarction (TIMI) Flow Grade 3 of MI Culprit Vessel at Initial Angiography (Co-primary Endpoint)</measure>
    <time_frame>At initial angiography, pre PCI</time_frame>
    <description>(TIMI) flow grade classification is used to assess coronary blood flow in acute coronary syndromes. grade 0:no reperfusion, grade 1: penetration without perfusion, grade 2: Partial reperfusion, grade 3: complete perfusion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ST-segment Elevation Resolution Pre PCI ≥70% (Co-primary Endpoint)</measure>
    <time_frame>Between baseline and PCI</time_frame>
    <description>ST segment elevation resolution is the mean ST elevation pre-hospital minus the mean STelevation pre-PCI divided by the mean ST elevation pre-hospital. It is expressed as a percentage and split in 2 categories , complete (≥70%) versus incomplete (&lt;70%) resolution.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1st Composite Clinical Endpoint</measure>
    <time_frame>during the 30 days of treatment</time_frame>
    <description>death/MI/stroke/urgent revascularization/stent thrombosis. Adjudicated events except death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2nd Composite Clinical Endpoint</measure>
    <time_frame>within 30 days of study</time_frame>
    <description>Death/MI/urgent revascularization. Adjudicated events except death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Definite Stent Thrombosis</measure>
    <time_frame>during 30 days of treatment</time_frame>
    <description>Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation. It is an adjudicated endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TIMI Flow Grade 3 Post -PCI</measure>
    <time_frame>at coroangiography post-PCI</time_frame>
    <description>TIMI) flow grade 3 is complete perfusion post-PCI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ST Segment Elevation Resolution Post-PCI &gt;= 70%</measure>
    <time_frame>Between baseline and ECG 60 mn post-PCI</time_frame>
    <description>ST segment elevation resolution post PCI &gt;=70% is defined as complete resolution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombotic Bail-out With GPIIb/IIIa Inhibitors at Initial PCI</measure>
    <time_frame>during PCI</time_frame>
    <description>Glycoprotein (GP) IIb/IIIa inhibitors are often used as a rescue or bailout therapy to manage complications arising during percutaneous coronary intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Bleeds Within 48 Hours</measure>
    <time_frame>within 48 hours of first dose</time_frame>
    <description>non CABG related bleeds, (PLATO definition) include Life threatening and other major bleeds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minor and Major Bleedings Within 48 Hours</measure>
    <time_frame>within 48 hours of first dose</time_frame>
    <description>non CABG related bleeds (PLATO definition)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Bleeds After 48 Hours</measure>
    <time_frame>after 48hours post-first dose</time_frame>
    <description>non CABG related bleeds (PLATO definition) include life threatening and other major bleedings</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minor and Major Bleeds After 48 Hours</measure>
    <time_frame>after 48 hours post first dose</time_frame>
    <description>non CABG related bleeds (PLATO definition)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1875</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Segment Elevation Myocardial Infarction (STEMI)</condition>
  <arm_group>
    <arm_group_label>Ticagrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Loading dose of Ticagrelor (180 mg) followed by matching placebo. After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo followed by a loading dose of Ticagrelor (180 mg). After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Oral Ticagrelor loading dose (180 mg) followed by matching placebo</description>
    <arm_group_label>Ticagrelor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo followed by oral Ticagrelor loading dose (180 mg)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women must not be of child-bearing potential (1 year post-menopausal or surgically
             sterile).

          -  Symptoms of acute MI of more than 30 min but less than 6 hours

          -  New persistent ST-segment elevation ≥ 1 mm in two or more contiguous electrocardiogram
             (ECG) leads.

        Exclusion Criteria:

          -  Expected time to 1st PCI balloon inflation in the hospital, from the qualifying ECG is
             more than 120 minutes

          -  Contraindication to ticagrelor (refer to SmPC)

          -  Concomitant medication that may increase the risk of bleeding [e.g non steroidal
             anti-inflammatory drugs (NSAIDs), oral anticoagulant and / or fibrinolytics, planned
             or administered 24 hours before randomization]

          -  Any of the following conditions in the absence of a functioning implanted pacemaker:
             known SSS, second or third degree AVB, or documented syncope of suspected bradycardic
             origin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Judith Hsia, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pr Gilles Montalescot</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pitie Salpetriere Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Algiers</city>
        <country>Algeria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Blida</city>
        <country>Algeria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Herston</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Southport</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Woolloongabba</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Scarborough</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Odense C</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Århus</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aubervilliers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boulogne Billancourt</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bourges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chateauroux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Corbeil Essonnes Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Creteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>LAGNY SUR MARNE cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Le Chesnay</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Le Coudray</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lyon Cedex 04</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>MARSEILLE cedex 15</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Massy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Melun</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montauban</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montfermeil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>MONTREUIL Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Neuilly Sur Seine</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nimes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris Cedex 13</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>PARIS Cedex 15</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>PESSAC Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quincy sous Sénart</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rouen Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>TOURS Cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>TOURS cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>VANNES cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bad Friedrichshall</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bad Nauheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Darmstadt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Esslingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gießen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ludwigshafen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lüdenscheid</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Merseburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wuppertal</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pécs</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Arezzo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ascoli Piceno</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Forlì</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Grosseto</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Massa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seriate</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Alkmaar</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Den Bosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Terneuzen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>A Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hospitalet de Llobregat(Barcel</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santiago(A Coruña)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vigo(Pontevedra)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gävle</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Örebro</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ashford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Belfast</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Coventry</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Eastbourne</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hastings</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Middlesborough</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newcastle-Upon-Tyne</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Norwich</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Algeria</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Israel</country>
  </removed_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=482&amp;filename=D5130L00006_Protocol_Redacted.pdf</url>
    <description>D5130L00006_Protocol</description>
  </link>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=482&amp;filename=D5130L00006_CSR_Synopsis.pdf</url>
    <description>D5130L00006_CSR_Synopsis</description>
  </link>
  <results_reference>
    <citation>Montalescot G, van 't Hof AW, Lapostolle F, Silvain J, Lassen JF, Bolognese L, Cantor WJ, Cequier A, Chettibi M, Goodman SG, Hammett CJ, Huber K, Janzon M, Merkely B, Storey RF, Zeymer U, Stibbe O, Ecollan P, Heutz WM, Swahn E, Collet JP, Willems FF, Baradat C, Licour M, Tsatsaris A, Vicaut E, Hamm CW; ATLANTIC Investigators. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med. 2014 Sep 11;371(11):1016-27. doi: 10.1056/NEJMoa1407024. Epub 2014 Sep 1.</citation>
    <PMID>25175921</PMID>
  </results_reference>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2011</study_first_submitted>
  <study_first_submitted_qc>May 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2011</study_first_posted>
  <results_first_submitted>November 13, 2014</results_first_submitted>
  <results_first_submitted_qc>January 26, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 11, 2015</results_first_posted>
  <last_update_submitted>July 20, 2015</last_update_submitted>
  <last_update_submitted_qc>July 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart attack</keyword>
  <keyword>heart disease</keyword>
  <keyword>cardiovascular disease</keyword>
  <keyword>stroke</keyword>
  <keyword>reperfusion</keyword>
  <keyword>pre hospital settings</keyword>
  <keyword>ticagrelor</keyword>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were randomized in pre-hospital settings at 102 Emergency Medical Services between September 2011 and October 2013. 1875 patients were recruited in the study, 1862 consented patients were randomized.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Pre-hospital Ticagrelor</title>
          <description>Loading dose of Ticagrelor (180 mg) followed by matching placebo. After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.</description>
        </group>
        <group group_id="P2">
          <title>In-hospital Ticagrelor</title>
          <description>Placebo followed by a loading dose of Ticagrelor (180 mg). After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="909">based on randomized treatment</participants>
                <participants group_id="P2" count="953">based on randomized treatment</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Modified Intent to Treat Population</title>
              <participants_list>
                <participants group_id="P1" count="906">based on randomized treatment</participants>
                <participants group_id="P2" count="952">based on randomized treatment</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="908">based on actual treatment</participants>
                <participants group_id="P2" count="950">based on actual treatment</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="844">based on randomized treatment</participants>
                <participants group_id="P2" count="897">based on randomized treatment</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Had other reason</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pre-hospital Ticagrelor</title>
          <description>Loading dose of Ticagrelor (180 mg) followed by matching placebo. After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.</description>
        </group>
        <group group_id="B2">
          <title>In-hospital Ticagrelor</title>
          <description>Placebo followed by a loading dose of Ticagrelor (180 mg). After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="909"/>
            <count group_id="B2" value="953"/>
            <count group_id="B3" value="1862"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.6" spread="12.38"/>
                    <measurement group_id="B2" value="61.0" spread="12.49"/>
                    <measurement group_id="B3" value="60.8" spread="12.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="173"/>
                    <measurement group_id="B2" value="196"/>
                    <measurement group_id="B3" value="369"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="736"/>
                    <measurement group_id="B2" value="757"/>
                    <measurement group_id="B3" value="1493"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes mellitus</title>
          <units>patients</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="138"/>
                    <measurement group_id="B3" value="253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>no/unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="794"/>
                    <measurement group_id="B2" value="815"/>
                    <measurement group_id="B3" value="1609"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>TIMI risk score</title>
          <description>Thrombolysis in Myocardial Infarction (TIMI) is a scoring system based on independant predictors of mortality such as age, diabetes mellitus, history of hypertension, history of angina, ST segment elevation. The death rate at 30 days for the following scores are: 0-2: 0.8%-2.2%, 3-6: 4.4% -16.1%, score&gt;6: 23.4% to 35.9%.</description>
          <units>patients</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="552"/>
                    <measurement group_id="B2" value="573"/>
                    <measurement group_id="B3" value="1125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="337"/>
                    <measurement group_id="B2" value="365"/>
                    <measurement group_id="B3" value="702"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Killip class</title>
          <description>Killip class assesses the presence and severity of heart failure by physical examination. Class I :No rales, no 3rd heart sound. Class 2: Rales in &lt;1⁄2 lung field or presence of a 3rd heart sound. Class 3: Rales in &gt;1⁄2 lung field–pulmonary edema.Class 4 : Cardiogenic shock–determined clinically.</description>
          <units>patients</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="819"/>
                    <measurement group_id="B2" value="862"/>
                    <measurement group_id="B3" value="1681"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>II, III, IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>First medical contact</title>
          <units>patients</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>in ambulance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="689"/>
                    <measurement group_id="B2" value="723"/>
                    <measurement group_id="B3" value="1412"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>in emergency department</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="220"/>
                    <measurement group_id="B2" value="230"/>
                    <measurement group_id="B3" value="450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PCI</title>
          <description>Percutaneous coronary intervention (PCI) is a non-surgery intervention performed to open blocked coronary arteries and to restore arterial blood flow to the heart tissue.</description>
          <units>Patients</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="800"/>
                    <measurement group_id="B2" value="830"/>
                    <measurement group_id="B3" value="1630"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>type of PCI</title>
          <description>on patients with PCI</description>
          <units>patients</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>with stent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="760"/>
                    <measurement group_id="B2" value="776"/>
                    <measurement group_id="B3" value="1536"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>without stent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time between the 2 loading doses</title>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32" lower_limit="22" upper_limit="45"/>
                    <measurement group_id="B2" value="30" lower_limit="22" upper_limit="43"/>
                    <measurement group_id="B3" value="31" lower_limit="22" upper_limit="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Thrombolysis In Myocardial Infarction (TIMI) Flow Grade 3 of MI Culprit Vessel at Initial Angiography (Co-primary Endpoint)</title>
        <description>(TIMI) flow grade classification is used to assess coronary blood flow in acute coronary syndromes. grade 0:no reperfusion, grade 1: penetration without perfusion, grade 2: Partial reperfusion, grade 3: complete perfusion.</description>
        <time_frame>At initial angiography, pre PCI</time_frame>
        <population>mITT, on patients with non missing values</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-hospital Ticagrelor</title>
            <description>Loading dose of Ticagrelor (180 mg) followed by matching placebo. After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.</description>
          </group>
          <group group_id="O2">
            <title>In-hospital Ticagrelor</title>
            <description>Placebo followed by a loading dose of Ticagrelor (180 mg). After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Thrombolysis In Myocardial Infarction (TIMI) Flow Grade 3 of MI Culprit Vessel at Initial Angiography (Co-primary Endpoint)</title>
          <description>(TIMI) flow grade classification is used to assess coronary blood flow in acute coronary syndromes. grade 0:no reperfusion, grade 1: penetration without perfusion, grade 2: Partial reperfusion, grade 3: complete perfusion.</description>
          <population>mITT, on patients with non missing values</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="824"/>
                <count group_id="O2" value="856"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143"/>
                    <measurement group_id="O2" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8214</p_value>
            <p_value_desc>pvalue at 0.025 , adjusted for multiple comparisons</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.030</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.799</ci_lower_limit>
            <ci_upper_limit>1.327</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ST-segment Elevation Resolution Pre PCI ≥70% (Co-primary Endpoint)</title>
        <description>ST segment elevation resolution is the mean ST elevation pre-hospital minus the mean STelevation pre-PCI divided by the mean ST elevation pre-hospital. It is expressed as a percentage and split in 2 categories , complete (≥70%) versus incomplete (&lt;70%) resolution.</description>
        <time_frame>Between baseline and PCI</time_frame>
        <population>mITT, on patients with non missing values</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-hospital Ticagrelor</title>
            <description>Loading dose of Ticagrelor (180 mg) followed by matching placebo. After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.</description>
          </group>
          <group group_id="O2">
            <title>In-hospital Ticagrelor</title>
            <description>Placebo followed by a loading dose of Ticagrelor (180 mg). After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.</description>
          </group>
        </group_list>
        <measure>
          <title>ST-segment Elevation Resolution Pre PCI ≥70% (Co-primary Endpoint)</title>
          <description>ST segment elevation resolution is the mean ST elevation pre-hospital minus the mean STelevation pre-PCI divided by the mean ST elevation pre-hospital. It is expressed as a percentage and split in 2 categories , complete (≥70%) versus incomplete (&lt;70%) resolution.</description>
          <population>mITT, on patients with non missing values</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="774"/>
                <count group_id="O2" value="824"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6322</p_value>
            <p_value_desc>P value at 0.025 adjusted for multiple comparisons</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.074</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.801</ci_lower_limit>
            <ci_upper_limit>1.441</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>1st Composite Clinical Endpoint</title>
        <description>death/MI/stroke/urgent revascularization/stent thrombosis. Adjudicated events except death</description>
        <time_frame>during the 30 days of treatment</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-hospital Ticagrelor</title>
            <description>Loading dose of Ticagrelor (180 mg) followed by matching placebo. After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.</description>
          </group>
          <group group_id="O2">
            <title>In-hospital Ticagrelor</title>
            <description>Placebo followed by a loading dose of Ticagrelor (180 mg). After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.</description>
          </group>
        </group_list>
        <measure>
          <title>1st Composite Clinical Endpoint</title>
          <description>death/MI/stroke/urgent revascularization/stent thrombosis. Adjudicated events except death</description>
          <population>mITT</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="906"/>
                <count group_id="O2" value="952"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9056</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.027</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.661</ci_lower_limit>
            <ci_upper_limit>1.595</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>2nd Composite Clinical Endpoint</title>
        <description>Death/MI/urgent revascularization. Adjudicated events except death</description>
        <time_frame>within 30 days of study</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-hospital Ticagrelor</title>
            <description>Loading dose of Ticagrelor (180 mg) followed by matching placebo. After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.</description>
          </group>
          <group group_id="O2">
            <title>In-hospital Ticagrelor</title>
            <description>Placebo followed by a loading dose of Ticagrelor (180 mg). After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.</description>
          </group>
        </group_list>
        <measure>
          <title>2nd Composite Clinical Endpoint</title>
          <description>Death/MI/urgent revascularization. Adjudicated events except death</description>
          <population>mITT</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="906"/>
                <count group_id="O2" value="952"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4168</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.215</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.760</ci_lower_limit>
            <ci_upper_limit>1.942</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Definite Stent Thrombosis</title>
        <description>Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation. It is an adjudicated endpoint</description>
        <time_frame>during 30 days of treatment</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-hospital Ticagrelor</title>
            <description>Loading dose of Ticagrelor (180 mg) followed by matching placebo. After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.</description>
          </group>
          <group group_id="O2">
            <title>In-hospital Ticagrelor</title>
            <description>Placebo followed by a loading dose of Ticagrelor (180 mg). After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Definite Stent Thrombosis</title>
          <description>Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation. It is an adjudicated endpoint</description>
          <population>mITT</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="906"/>
                <count group_id="O2" value="952"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0307</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.189</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.042</ci_lower_limit>
            <ci_upper_limit>0.856</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TIMI Flow Grade 3 Post -PCI</title>
        <description>TIMI) flow grade 3 is complete perfusion post-PCI.</description>
        <time_frame>at coroangiography post-PCI</time_frame>
        <population>mITT, on patients with non missing TIMI flow grade values</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-hospital Ticagrelor</title>
            <description>Loading dose of Ticagrelor (180 mg) followed by matching placebo. After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.</description>
          </group>
          <group group_id="O2">
            <title>In-hospital Ticagrelor</title>
            <description>Placebo followed by a loading dose of Ticagrelor (180 mg). After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.</description>
          </group>
        </group_list>
        <measure>
          <title>TIMI Flow Grade 3 Post -PCI</title>
          <description>TIMI) flow grade 3 is complete perfusion post-PCI.</description>
          <population>mITT, on patients with non missing TIMI flow grade values</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="760"/>
                <count group_id="O2" value="784"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="625"/>
                    <measurement group_id="O2" value="630"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.344</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.132</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.876</ci_lower_limit>
            <ci_upper_limit>1.462</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ST Segment Elevation Resolution Post-PCI &gt;= 70%</title>
        <description>ST segment elevation resolution post PCI &gt;=70% is defined as complete resolution</description>
        <time_frame>Between baseline and ECG 60 mn post-PCI</time_frame>
        <population>mITT on patients with non missing ECG values</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-hospital Ticagrelor</title>
            <description>Loading dose of Ticagrelor (180 mg) followed by matching placebo. After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.</description>
          </group>
          <group group_id="O2">
            <title>In-hospital Ticagrelor</title>
            <description>Placebo followed by a loading dose of Ticagrelor (180 mg). After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.</description>
          </group>
        </group_list>
        <measure>
          <title>ST Segment Elevation Resolution Post-PCI &gt;= 70%</title>
          <description>ST segment elevation resolution post PCI &gt;=70% is defined as complete resolution</description>
          <population>mITT on patients with non missing ECG values</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="713"/>
                <count group_id="O2" value="743"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="410"/>
                    <measurement group_id="O2" value="390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0547</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.225</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.996</ci_lower_limit>
            <ci_upper_limit>1.506</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Thrombotic Bail-out With GPIIb/IIIa Inhibitors at Initial PCI</title>
        <description>Glycoprotein (GP) IIb/IIIa inhibitors are often used as a rescue or bailout therapy to manage complications arising during percutaneous coronary intervention.</description>
        <time_frame>during PCI</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-hospital Ticagrelor</title>
            <description>Loading dose of Ticagrelor (180 mg) followed by matching placebo. After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.</description>
          </group>
          <group group_id="O2">
            <title>In-hospital Ticagrelor</title>
            <description>Placebo followed by a loading dose of Ticagrelor (180 mg). After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Thrombotic Bail-out With GPIIb/IIIa Inhibitors at Initial PCI</title>
          <description>Glycoprotein (GP) IIb/IIIa inhibitors are often used as a rescue or bailout therapy to manage complications arising during percutaneous coronary intervention.</description>
          <population>mITT</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="906"/>
                <count group_id="O2" value="952"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1660</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.803</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.588</ci_lower_limit>
            <ci_upper_limit>1.096</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Bleeds Within 48 Hours</title>
        <description>non CABG related bleeds, (PLATO definition) include Life threatening and other major bleeds</description>
        <time_frame>within 48 hours of first dose</time_frame>
        <population>Safety</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-hospital Ticagrelor</title>
            <description>Loading dose of Ticagrelor (180 mg) followed by matching placebo. After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.</description>
          </group>
          <group group_id="O2">
            <title>In-hospital Ticagrelor</title>
            <description>Placebo followed by a loading dose of Ticagrelor (180 mg). After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Major Bleeds Within 48 Hours</title>
          <description>non CABG related bleeds, (PLATO definition) include Life threatening and other major bleeds</description>
          <population>Safety</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="908"/>
                <count group_id="O2" value="950"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Minor and Major Bleedings Within 48 Hours</title>
        <description>non CABG related bleeds (PLATO definition)</description>
        <time_frame>within 48 hours of first dose</time_frame>
        <population>Safety</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-hospital Ticagrelor</title>
            <description>Loading dose of Ticagrelor (180 mg) followed by matching placebo. After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.</description>
          </group>
          <group group_id="O2">
            <title>In-hospital Ticagrelor</title>
            <description>Placebo followed by a loading dose of Ticagrelor (180 mg). After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Minor and Major Bleedings Within 48 Hours</title>
          <description>non CABG related bleeds (PLATO definition)</description>
          <population>Safety</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="908"/>
                <count group_id="O2" value="950"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Bleeds After 48 Hours</title>
        <description>non CABG related bleeds (PLATO definition) include life threatening and other major bleedings</description>
        <time_frame>after 48hours post-first dose</time_frame>
        <population>safety</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-hospital Ticagrelor</title>
            <description>Loading dose of Ticagrelor (180 mg) followed by matching placebo. After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.</description>
          </group>
          <group group_id="O2">
            <title>In-hospital Ticagrelor</title>
            <description>Placebo followed by a loading dose of Ticagrelor (180 mg). After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Major Bleeds After 48 Hours</title>
          <description>non CABG related bleeds (PLATO definition) include life threatening and other major bleedings</description>
          <population>safety</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="908"/>
                <count group_id="O2" value="950"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Minor and Major Bleeds After 48 Hours</title>
        <description>non CABG related bleeds (PLATO definition)</description>
        <time_frame>after 48 hours post first dose</time_frame>
        <population>safety</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-hospital Ticagrelor</title>
            <description>Loading dose of Ticagrelor (180 mg) followed by matching placebo. After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.</description>
          </group>
          <group group_id="O2">
            <title>In-hospital Ticagrelor</title>
            <description>Placebo followed by a loading dose of Ticagrelor (180 mg). After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Minor and Major Bleeds After 48 Hours</title>
          <description>non CABG related bleeds (PLATO definition)</description>
          <population>safety</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="908"/>
                <count group_id="O2" value="950"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>within 30 days of study</time_frame>
      <desc>Actual Treatment Safety analysis set concerns 1858 patients - Ticagrelor pre-hosp:908 and Ticagrelor in-hosp: 950. 4 patients receiveived study medication not according to randomization assignment</desc>
      <group_list>
        <group group_id="E1">
          <title>Ticagrelor In-Hosp</title>
          <description>Placebo followed by a loading dose of Ticagrelor (180 mg). After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.</description>
        </group>
        <group group_id="E2">
          <title>Ticagrelor Pre-Hosp</title>
          <description>Loading dose of Ticagrelor (180 mg) followed by matching placebo. After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="143" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="140" subjects_at_risk="908"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>LEUKOCYTOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="950"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>ANGINA UNSTABLE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>AORTIC VALVE INCOMPETENCE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>ARTERIOSPASM CORONARY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="950"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK COMPLETE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>BRADYCARDIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="950"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>CARDIAC ASTHMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="950"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE ACUTE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>CARDIAC TAMPONADE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>CARDIOGENIC SHOCK</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="950"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>CARDIOPULMONARY FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>CONGESTIVE CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>DRESSLER'S SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>INTERVENTRICULAR SEPTUM RUPTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>INTRACARDIAC THROMBUS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>LEFT VENTRICULAR DYSFUNCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>LEFT VENTRICULAR FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL RUPTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>PALPITATIONS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>PERICARDIAL EFFUSION</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>PERICARDITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>TORSADE DE POINTES</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>VENTRICLE RUPTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>VENTRICULAR EXTRASYSTOLES</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>VENTRICULAR FIBRILLATION</sub_title>
                <counts group_id="E1" events="30" subjects_affected="30" subjects_at_risk="950"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>VENTRICULAR SEPTAL DEFECT ACQUIRED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>VENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="950"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="908"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>VENTRICULAR SEPTAL DEFECT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="908"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>COLITIS ISCHAEMIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>GASTRIC ULCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>GASTRIC ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL TELANGIECTASIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>HAEMATEMESIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>HAEMATOCHEZIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>INTESTINAL ISCHAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>MELAENA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>RECTAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>RETROPERITONEAL HAEMATOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="908"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>CARDIAC DEATH</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>DEVICE MALFUNCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>MULTI-ORGAN FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="950"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>SUDDEN CARDIAC DEATH</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>SUDDEN DEATH</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>THROMBOSIS IN DEVICE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>VESSEL PUNCTURE SITE HAEMATOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>BILIARY COLIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS ACUTE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="908"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BILIARY SEPSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS VIRAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>GROIN INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>LUNG INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>RELAPSING FEVER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>SEPTIC SHOCK</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>SKIN INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>UROSEPSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>FEMORAL NECK FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HAEMATOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>PROCEDURAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>SUBDURAL HAEMATOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>TRAUMATIC HAEMATOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>UPPER LIMB FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>VASCULAR PSEUDOANEURYSM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="908"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>HAEMOGLOBIN DECREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>HEPATIC ENZYME INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>NUTRITIONAL CONDITION ABNORMAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>PLATELET COUNT DECREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>TROPONIN INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="908"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>MUSCULOSKELETAL CHEST PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>PAIN IN JAW</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>PATHOLOGICAL FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>ADRENAL ADENOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>BLADDER NEOPLASM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>CARDIAC MYXOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA (MALT TYPE)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>RECTAL NEOPLASM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>RENAL CANCER METASTATIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CEREBRAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>DYSARTHRIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGE INTRACRANIAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>HEMIPARESIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>LACUNAR INFARCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>PRESYNCOPE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>TRANSIENT ISCHAEMIC ATTACK</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>CONFUSIONAL STATE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>SUICIDE ATTEMPT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>RENAL COLIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="908"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="950"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>ACUTE RESPIRATORY DISTRESS SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>ATELECTASIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>DIAPHRAGMATIC PARALYSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>HAEMOTHORAX</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>LUNG DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>RESPIRATORY DISTRESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="908"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>RASH PRURITIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="908"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>AORTIC DISSECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>ARTERY DISSECTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>HAEMATOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>HAEMODYNAMIC INSTABILITY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>ORTHOSTATIC HYPOTENSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>THROMBOPHLEBITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="908"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3.0</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="529" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="469" subjects_at_risk="908"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="908"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="908"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="908"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="908"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="908"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="908"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="908"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This urgent setting study included 8.6% of patients with symptoms of MI in ambulance but having finally not a STEMI diagnosis in cathlab.
No prespecified hypothesis and procedure for adjustment was made on secondary endpoints.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Tomas Andersson MD</name_or_title>
      <organization>AstraZeneca</organization>
      <phone>00 46 31 77 61966</phone>
      <email>tomas.lg.andersson@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

